Jump to content

Form:RCT Study: Difference between revisions

From CAMIH
← Older edit
No edit summary
No edit summary
 
(12 intermediate revisions by 2 users not shown)
Line 102: Line 102:
|-
|-
! Types of cancer: {{#info: "Other Cancers" means that only a subpopulation was specified, but further unspecified cancer types were included|note}}
! Types of cancer: {{#info: "Other Cancers" means that only a subpopulation was specified, but further unspecified cancer types were included|note}}
| {{{field|Types of cancer|input type=text with autocomplete|mandatory|default=?|delimiter=,|values=Adrenal Cancer,Anal Cancer,Bile Duct Cancer,Bone and Soft Tissue Cancers, Bone and Soft Tissue Cancers - Osteosarcoma,Bone and Soft Tissue Cancers - Ewing Sarcoma,Bone and Soft Tissue Cancers - Chondrosarcoma,Bone and Soft Tissue Cancers - Rhabdomyosarcoma,Bone and Soft Tissue Cancers – Liposarcoma,Brain and Central Nervous System (CNS) Cancers,Brain and Central Nervous System (CNS) Cancers - Astrocytoma,Brain and Central Nervous System (CNS) Cancers - Glioblastoma,Brain and Central Nervous System (CNS) Cancers - High-Grade Glioma,Brain and Central Nervous System (CNS) Cancers - Meningioma,Breast Cancer,Breast Cancer - Ductal Carcinoma,Breast Cancer - Lobular Carcinoma,Breast Cancer - Inflammatory Breast Cancer,Breast Cancer - Triple-Negative Breast Cancer,Carcinosarcoma,Colorectal Cancer,Colorectal Cancer - Colon Cancer,Colorectal Cancer - Rectal Cancer,Eye Cancer,Eye Cancer - Retinoblastoma,Gastrointestinal Cancers,Gastrointestinal Cancers - Gallbladder Cancer,Gastrointestinal Cancers - Gastric (Stomach) Cancer,Gastrointestinal Cancers - Esophageal Cancer,Gastrointestinal Cancers - Pancreatic Cancer,Gastrointestinal Cancers - Liver Cancer,Genitourinary Cancers,Genitourinary Cancers - Bladder Cancer,Genitourinary Cancers - Kidney (Renal) Cancer,Genitourinary Cancers - Testicular Cancer,Genitourinary Cancers - Urethral Cancer,Gynecologic Cancers,Gynecologic Cancers - Ovarian Cancer,Gynecologic Cancers - Cervical Cancer,Gynecologic Cancers - Uterine Cancer,Gynecologic Cancers - Endometrial Cancer,Gynecologic Cancers - Vulvar Cancer,Head and Neck Cancers, Head and Neck Cancers - Oral Cancer,Head and Neck Cancers - Oropharyngeal Cancer,Head and Neck Cancers - Laryngeal Cancer,Head and Neck Cancers - Nasopharyngeal Cancer,Head and Neck Cancers - Tongue Cancer,Head and Neck Cancers - Thyroid Cancer,Head and Neck Cancers - Ethmoid Sinus Cancer,Hematologic Cancers, Hematologic Cancers - Leukemia (Acute Lymphocytic/Acute Myeloid/Chronic Lymphocytic/Chronic Myeloid), Hematologic Cancers - Lymphoma (Hodgkin and Non-Hodgkin),Hematologic Cancers - Multiple Myeloma,Lung Cancer,Lung Cancer - Small Cell Lung Cancer,Lung Cancer - Non-Small Cell Lung Cancer,Mesothelioma,Neuroblastoma,Prostate Cancer,Skin Cancer,Skin Cancer - Basal Cell Carcinoma,Skin Cancer - Squamous Cell Carcinoma,Skin Cancer – Melanoma,Stomach Cancer,Solid Malignancies,Thymoma and Thymic Carcinoma,Unspecified Sarcoma,Other Cancers,NI,?}}}
| {{{field|Types of cancer|input type=text with autocomplete|mandatory|default=?|delimiter=,|values=Adrenal Cancer,Anal Cancer,Bile Duct Cancer,Bone and Soft Tissue Cancers, Bone and Soft Tissue Cancers - Osteosarcoma,Bone and Soft Tissue Cancers - Ewing Sarcoma,Bone and Soft Tissue Cancers - Chondrosarcoma,Bone and Soft Tissue Cancers - Rhabdomyosarcoma,Bone and Soft Tissue Cancers – Liposarcoma,Brain and Central Nervous System (CNS) Cancers,Brain and Central Nervous System (CNS) Cancers - Astrocytoma,Brain and Central Nervous System (CNS) Cancers - Glioblastoma,Brain and Central Nervous System (CNS) Cancers - High-Grade Glioma,Brain and Central Nervous System (CNS) Cancers - Meningioma,Breast Cancer,Breast Cancer - Ductal Carcinoma,Breast Cancer - Lobular Carcinoma,Breast Cancer - Inflammatory Breast Cancer,Breast Cancer - Triple-Negative Breast Cancer,Carcinosarcoma,Chest Cancer,Colorectal Cancer,Colorectal Cancer - Colon Cancer,Colorectal Cancer - Rectal Cancer,Eye Cancer,Eye Cancer - Retinoblastoma,Gastrointestinal Cancers,Gastrointestinal Cancers - Gallbladder Cancer,Gastrointestinal Cancers - Gastric (Stomach) Cancer,Gastrointestinal Cancers - Esophageal Cancer,Gastrointestinal Cancers - Pancreatic Cancer,Gastrointestinal Cancers - Liver Cancer,Genitourinary Cancers,Genitourinary Cancers - Bladder Cancer,Genitourinary Cancers - Kidney (Renal) Cancer,Genitourinary Cancers - Testicular Cancer,Genitourinary Cancers - Urethral Cancer,Gynecologic Cancers,Gynecologic Cancers - Ovarian Cancer,Gynecologic Cancers - Cervical Cancer,Gynecologic Cancers - Uterine Cancer,Gynecologic Cancers - Endometrial Cancer,Gynecologic Cancers - Vulvar Cancer,Head and Neck Cancers, Head and Neck Cancers - Oral Cancer,Head and Neck Cancers - Oropharyngeal Cancer,Head and Neck Cancers - Laryngeal Cancer,Head and Neck Cancers - Nasopharyngeal Cancer,Head and Neck Cancers - Tongue Cancer,Head and Neck Cancers - Thyroid Cancer,Head and Neck Cancers - Ethmoid Sinus Cancer,Hematologic Cancers, Hematologic Cancers - Leukemia (Acute Lymphocytic/Acute Myeloid/Chronic Lymphocytic/Chronic Myeloid), Hematologic Cancers - Lymphoma (Hodgkin and Non-Hodgkin),Hematologic Cancers - Multiple Myeloma,Lung Cancer,Lung Cancer - Small Cell Lung Cancer,Lung Cancer - Non-Small Cell Lung Cancer,Mesothelioma,Neuroblastoma,Prostate Cancer,Skin Cancer,Skin Cancer - Basal Cell Carcinoma,Skin Cancer - Squamous Cell Carcinoma,Skin Cancer – Melanoma,Stomach Cancer,Solid Malignancies,Thymoma and Thymic Carcinoma,Unspecified Sarcoma,Other Cancers,NI,?}}}
|-
|-
! Cancer stage: {{#info: Early Stage: generally refers to cancer that is localized to the area where it started, mostly stages I and II;
! Cancer stage: {{#info: Early Stage: generally refers to cancer that is localized to the area where it started, mostly stages I and II;
Line 164: Line 164:


'''Order number:''' {{{field|Order number|input type=text|mandatory|default=1}}}
'''Order number:''' {{{field|Order number|input type=text|mandatory|default=1}}}
'''Arm topic:''' {{{field|Arm topic|input type=tokens|mandatory|delimiter=,|values=Aloe vera,Boswellia serrata,Cannabinoids,Carnitine,Curcumin,Electroacupuncture,Enzymes (bromelain papain),Folic acid,Ginger,Ginkgo,Green tea (EGCG),Guarana,Low-carbohydrate or ketogenic diet,Lycopene,Reflexology,Resveratrol,Selenium,Vitamin A (beta-carotene),Vitamin B1,Vitamin B12,Vitamin B6,Vitamin C,Vitamin D,Vitamin E,Zeolites,Zinc,NI,?}}}


{{{end template}}}
{{{end template}}}
Line 175: Line 177:
'''Outcome type:''' {{#info: As specificed by the authors| note}} {{{field|Outcome type|input type=radiobutton|mandatory|default=?|values=?,Primary,Secondary,Others,NI}}}
'''Outcome type:''' {{#info: As specificed by the authors| note}} {{{field|Outcome type|input type=radiobutton|mandatory|default=?|values=?,Primary,Secondary,Others,NI}}}


'''Outcome name:''' {{{field|Outcome name|input type=text with autocomplete|mandatory|default=?|delimiter=,|values=Additional medication,Anorexia/Cachexia,Antibodies,Anxiety,Appetite,Arterial inflow,BMD (Bone Mineral Density),Body composition,Carnitine level,Carotenoid concentration,Cerebral oedema,CINV (Chemotherapy-Induced Nausea and Vomiting),Cognitive functioning,Cognitive impairment,Depression,Dermatitis,DFS (Disease-Free Survival),Diarrhoe,Distress,Dysgeusia,EFS (Event-Free Survival),Ejection fraction,Emesis,Erectile dysfunction,Erythema,Esophagitis,Fatigue,Fever,Fibrosis,Folic acid level,Frequency of rescue analgesics,Functionality,Haematological indices,Haematological toxicity,Hand-foot syndrome,Hand grip strength,Hepatotoxicity,Hot flushes,Hormone level,Ileus (intestinal obstruction),Incidence of acute GVHD (Graft-Versus-Host Disease),Infection,Interaction with cancer treatment,Laboratory parameters,Length of hospital stay,LFS (Local-Free Survival),Lymphedema,Menopausal symptoms,Mental status/ function,MFS (Metastases-Free Survival),Mood/Affect,Mortality rate,MTD (Maximum Tolerated Dose),Mucositis,Musculoskeletal symptoms,Nausea,Nausea and Vomiting,Nerve conductive velocity,Neurotoxicity,Neutropenia,Non-haematological indices,Nutrition status,Objective signs and subjective symptoms,Oral ulcus,OS (Overall Survival),Ototoxicity,Pain,PD (Pharmacodynamics),Performance Status,Peripheral neuropathy,PFS (Progression-Free Survival),Pharyngitis,Physical functioning,PK (Pharmacokinetics),Postoperative opiate consumption,PSADT (Prostate-Specific Antigen Doubling Time),PSA level (Prostate-Specific Antigen),Quality of life,Recurrence rate,Reduction of complication rates,REE (Resting Energy Expenditure),Relaxation,Restoration of bowel function after surgery,RFS (Recurrence-Free Survival),Salivary gland function,Selenium level,Seroconversion,Shoulder mobility,Side effects of androgen deprivation/suppression,Side effects of tooth extraction,Skeletal morbidity-free survival,Sleep,Stress,Taste alteration,Tea polyphenol uptake,Thromboembolic event rates,Toxicity,Treatment interruption,Tumor progression,Tumor response,Vaginal atrophy,Vitamin A level,Vitamin B6 level,Vitamin B12 level,Vitamin B17 level,Vitamin C level,Vitamin D level,Vitamin E level,Vomiting,Weight,Well-being,Wound healing,Wound odour,Xerostomia,Zinc level,Unspecified effects,NI,?}}}
'''Outcome name:''' {{{field|Outcome name|input type=text with autocomplete|mandatory|default=?|delimiter=,|values=Additional medication,Anorexia/Cachexia,Antibodies,Anxiety,Appetite,Arterial inflow,BMD (Bone Mineral Density),Body composition,Carnitine level,Carotenoid concentration,Cerebral oedema,CINV (Chemotherapy-Induced Nausea and Vomiting),Cognitive functioning,Cognitive impairment,Depression,Dermatitis,DFS (Disease-Free Survival),Diarrhoe,Distress,Dysgeusia,Ejection fraction,Erectile dysfunction,Erythema,Esophagitis,Fatigue,Fever,Fibrosis,Folic acid level,Functionality,Haematological indices,Haematological toxicity,Hand-foot syndrome,Hand grip strength,Hormone level,Ileus (intestinal obstruction),Incidence of acute GVHD (Graft-Versus-Host Disease),Infection,Interaction with cancer treatment,Laboratory parameters,Length of hospital stay,Lymphedema,Menopausal symptoms,Mental status/ function,Mood/Affect,Mortality rate,Mucositis,Musculoskeletal symptoms,Nausea,Nausea and Vomiting,Nerve conduction velocity,Neurotoxicity,Neutropenia,Non-haematological indices,Nutrition status,Objective signs and subjective symptoms,Oral ulcus,OS (Overall Survival),Ototoxicity,Pain,PD (Pharmacodynamics),Performance Status,Peripheral neuropathy,PFS (Progression-Free Survival),Pharyngitis,Physical functioning,PK (Pharmacokinetics),Postoperative morbidity/ complications,PSA level (Prostate-Specific Antigen),Quality of life,Recurrence rate,REE (Resting Energy Expenditure),Relaxation,RFS (Recurrence-Free Survival),Salivary gland function,Selenium level,Seroconversion,Sleep,Stomatitis,Stress,Symptom load,Taste alteration,Tea polyphenol uptake,Thromboembolic event rates,Toxicity,Treatment interruption,Tumor progression,Tumor response,Vaginal atrophy,Vitamin A level,Vitamin B6 level,Vitamin B12 level,Vitamin B17 level,Vitamin C level,Vitamin D level,Vitamin E level,Vomiting,Weight,Well-being,Wound healing,Wound odour,Xerostomia,Zinc level,Unspecified effects,NI,?}}}


'''Outcome specification:''' {{{field|Outcome specification|input type=textarea|default=?}}}
'''Outcome specification:''' {{{field|Outcome specification|input type=textarea|default=?}}}


'''Type of measurement:''' {{{field|Type of measurement|input type=tokens|mandatory|default=?|delimiter=,|values=AQoL-8D (Assessment of Quality of Life),ASAT (Auditory Sustained Attention Test),Atomic absorption,Audiogram,AUSCAN (Australian/Canadian Osteoarthritis Hand Index),BCPT (Breast Cancer Prevention Symptom Scales),BFI (Brief Fatigue Inventory),BIA (Bioelectrical impedance analysis),Blood Test,BPI-SF (Brief Pain Inventory - Short Form),CES-D (Center for Epidemiologic Studies - Depression Scale),Chemiluminescent immunoassay,CTCAE (Common Terminology Criteria of Adverse Events),Cystoscopy,Diary questionnaire,DXA (Dual energy X-ray Absorptiometry),Dynamometer,Echo-color Doppler,ECOG Performance Status Scale (Eastern Cooperative Oncology Group),Electronic monitoring device,Electrophysiological evaluation,ELISA protocol (Enzyme-Linked Immunoabsorbent Assay),EORTC QLQ (European Organisation for Research and Treatment of Cancer Core/ Quality of Life questionnaire),ESAS (Edmonton Symptom Assessment Scale),FAACT (Functional Assessment of Anorexia-Cachexia Therapy),FACIT (Functional Assessment of Chronic Illness Therapy),FACT (Functional Assessment of Cancer Therapy),FGS (Hughes' Functional Grading Scale),FIQ (Fibromyalgia Impact Questionnaire),FLIE (Functional Living Index for Emesis),Genitourinary atrophy self-assessment tool,GFAAS (Graphite Furnace Atomic Absorption Spectrometry),Global Charter Fatigue Scale,HADS (Hospital Anxiety and Depression Scale),HAQ-DI (Health Assessment Questionnaire-Disability Index),HFRDIS (Hot Flash Related Daily Interference Scale),HFS (Hot Flush Score),HGST Maximum (Handgrip Strength Test),Histological examination,HNQR (Head and Neck Radiotherapy Questionnaire),HSCS (High Sensitivity Cognitive Screen),ICI Test (Intracavernosal Injection Test),IIEF (International Index of Erectile Function),Interview,KPS (Karnofsky Performance Status),LASA (Linear Analogue Self-Assessment),LENT SOMA Scale (Late Effects on Normal Tissues/ Subjective Objective Management Analysis),MADRS (Montgomery-Asberg Depression Rating Scale),MAT (Multinational Association of Supportive Care in Cancer-Antiemesis Tool),McDonald criteria,Measuring tape,MENQOL (Menopause-Specific Quality of Life),MFI-20 (Multidimensional Fatigue Inventory-20),MMSE (Mini-Mental State Exam),MOS SF-12 (Medical Outcomes Study/ 12-Item Short Form Health Survey),MPQ-SF (McGill Pain Questionnaire - Short Form),MRI (Magnetic Resonance Imaging),NCI-CTC v.2 (National Cancer Institute-Common Toxic Criteria),NCI Grading Scale (National Cancer Institute),NDS (Neurological Disability Score),Neurologic examination,Neuropathy specific question,NRS (Numeric Rating Scale),NRS (Nutritional Risk Screening),NSS (Neurological Symptom Score),Observation,OMAS (Oral Mucositis Assessment Scale),Otoacoustic Emissions Testing,PAC-QoL (Patient Assessment of Constipation - Quality of Life),PGIC (Physician Global Impression of Change),PG-SGA (Patient-Generated Subjective Global Assessment),PHLF (Post Hepatectomy Liver Failure),PHS (Cognitive subscale of the Perceived Health Scale),pH-value,Physical examination,Physical functioning (grip strength;6 minute walk;leg extension),POMS (Profile of Mood States),PoSSe (Postoperative Symptom Severity Scale),Postoperative morbidity/complications (classification according to Clavien-Dindo),PROMIS (Patient-Reported Outcomes Measurement Information System),PSQ (Patient Satisfaction Questionnaire),PSQI (Pittsburgh Sleep Quality Index),QoR-40 (Quality of Recovery-40 Questionnaire),RDS (Radiation Dermatitis Severity),RECIST 1.0 Criteria (Response Evaluation Criteria in Solid Tumors),Reidel-Seiffer tuning fork,Rhodes Inventory of Nausea,RPSAS (Radiation Proctopathy System Assessment Scale),RTOG Acute Radiation Morbidity Scoring Criteria (Radiation Therapy Oncology Group),Scale,Scintigraphy,Self-developed measurement instrument,SF-36 (Short Form-36 Health Survey),SGIC (Subject Global Impression of Change),SI (Symptom Inventory questionnaire),SOMA (Subjective Objective Medical management and Analytic evaluation of injury),SPECT (Single Photon Emission Computed Tomography),Spectrophotometry,SPPB (Short Physical Performance Battery),Symptom experience diary (NCCTG),Thermometer,Three-stimulus drop technique (by Henkin),TMT (Trail Making Test),TNS (Total Neuropathy Score),Ultrasonography,Unspecified questionnaire,Urinalysis,VAS (Visual Analogue Scale),VMI (Vaginal Maturation Index),VNS (Verbal Numerical Scale),Volometer,Western Ontario and McMaster Osteoarthritis Index,WHO-Scale (World Health Organisation),Wound volume,NI,NA,?}}}
'''Type of measurement:''' {{{field|Type of measurement|input type=tokens|mandatory|default=?|delimiter=,|values=AQoL-8D (Assessment of Quality of Life),ASAT (Auditory Sustained Attention Test),Atomic absorption,Audiogram,AUSCAN (Australian/Canadian Osteoarthritis Hand Index),BCPT (Breast Cancer Prevention Symptom Scales),BDI (Beck Depression Inventory),BFI (Brief Fatigue Inventory),BIA (Bioelectrical impedance analysis),Blood Test,BPI-SF (Brief Pain Inventory - Short Form),CES-D (Center for Epidemiologic Studies - Depression Scale),Chemiluminescent immunoassay,CNPI (Checklist of Non-Verbal Pain Indicators),CSSP (Catterall Skin Scoring Profile),CT (Computed Tomography),CTCAE (Common Terminology Criteria of Adverse Events),Cystoscopy,Diary questionnaire,DXA (Dual energy X-ray Absorptiometry),Dynamometer,Echo-color Doppler,ECOG Performance Status Scale (Eastern Cooperative Oncology Group),Electronic monitoring device,Electrophysiological evaluation,ELISA protocol (Enzyme-Linked Immunoabsorbent Assay),EORTC QLQ (European Organisation for Research and Treatment of Cancer Core/ Quality of Life questionnaire),ESAS (Edmonton Symptom Assessment Scale),FAACT (Functional Assessment of Anorexia-Cachexia Therapy),FACIT (Functional Assessment of Chronic Illness Therapy),FACT (Functional Assessment of Cancer Therapy),FGS (Hughes' Functional Grading Scale),FIQ (Fibromyalgia Impact Questionnaire),FLIE (Functional Living Index for Emesis),Genitourinary atrophy self-assessment tool,GFAAS (Graphite Furnace Atomic Absorption Spectrometry),Global Charter Fatigue Scale,HADS (Hospital Anxiety and Depression Scale),HAQ-DI (Health Assessment Questionnaire-Disability Index),HFRDIS (Hot Flash Related Daily Interference Scale),HFS (Hot Flush Score),HGST Maximum (Handgrip Strength Test),Histological examination,HNQR (Head and Neck Radiotherapy Questionnaire),HSCS (High Sensitivity Cognitive Screen),ICI Test (Intracavernosal Injection Test),IIEF (International Index of Erectile Function),Interview,KPS (Karnofsky Performance Status),LASA (Linear Analogue Self-Assessment),LENT SOMA Scale (Late Effects on Normal Tissues/ Subjective Objective Management Analysis),MADRS (Montgomery-Asberg Depression Rating Scale),MAT (Multinational Association of Supportive Care in Cancer-Antiemesis Tool),McDonald criteria,MDASI (M. D. Anderson Symptom Inventory),Measuring tape,MENQOL (Menopause-Specific Quality of Life),MFI-20 (Multidimensional Fatigue Inventory-20),MMSE (Mini-Mental State Exam),Morbidity rating scale (by Dische),MOS SF-12 (Medical Outcomes Study/ 12-Item Short Form Health Survey),MPQ-SF (McGill Pain Questionnaire - Short Form),MRI (Magnetic Resonance Imaging),MRS (Mood Rating Scale),MYCaW (Measure Yourself Concerns and Wellbeing),NCI-CTC v.2 (National Cancer Institute-Common Toxic Criteria),NCI Grading Scale (National Cancer Institute),NDS (Neurological Disability Score),Neurologic examination,Neuropathy specific question,NRS (Numeric Rating Scale),NRS (Nutritional Risk Screening),NSS (Neurological Symptom Score),Observation,OMAS (Oral Mucositis Assessment Scale),Otoacoustic Emissions Testing,PAC-QoL (Patient Assessment of Constipation - Quality of Life),PGIC (Physician Global Impression of Change),PG-SGA (Patient-Generated Subjective Global Assessment),PHLF (Post Hepatectomy Liver Failure),PHS (Cognitive subscale of the Perceived Health Scale),pH-value,Physical examination,Physical functioning (grip strength;6 minute walk;leg extension),POMS (Profile of Mood States),PoSSe (Postoperative Symptom Severity Scale),Postoperative morbidity/complications (classification according to Clavien-Dindo),PROMIS (Patient-Reported Outcomes Measurement Information System),PSQ (Patient Satisfaction Questionnaire),PSQI (Pittsburgh Sleep Quality Index),QoR-40 (Quality of Recovery-40 Questionnaire),RDS (Radiation Dermatitis Severity),RECIST 1.0 Criteria (Response Evaluation Criteria in Solid Tumors),Reidel-Seiffer tuning fork,Rhodes Inventory of Nausea,RPSAS (Radiation Proctopathy System Assessment Scale),RTOG Acute Radiation Morbidity Scoring Criteria (Radiation Therapy Oncology Group),Scale,SCID (Structured Clinical Interview for DSM IV),Scintigraphy,Self-developed measurement instrument,SF-36 (Short Form-36 Health Survey),SF-MPQ (Short-Form McGill Pain Questionnaire),SGIC (Subject Global Impression of Change),SI (Symptom Inventory questionnaire),SOMA (Subjective Objective Medical management and Analytic evaluation of injury),SPECT (Single Photon Emission Computed Tomography),Spectrophotometry,SPPB (Short Physical Performance Battery),STAI (State-Trait-Anxiety-Inventory),Symptom experience diary (NCCTG),Thermometer,Three-stimulus drop technique (by Henkin),Tissue testing,TMT (Trail Making Test),TNS (Total Neuropathy Score),Ultrasonography,Unspecified questionnaire,Urinalysis,VAS (Visual Analogue Scale),VMI (Vaginal Maturation Index),VNS (Verbal Numerical Scale),Volometer,Western Ontario and McMaster Osteoarthritis Index,WHO-Scale (World Health Organisation),Wound volume,NI,NA,?}}}


'''Results during intervention:''' {{{field|Results during intervention|input type=textarea|mandatory|default=?}}}
'''Results during intervention:''' {{#info: ''Results during intervention'' means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.|note}}
'''Results after intervention:''' {{#info: If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under ''Results after intervention'' under the headline "Overall".|note}}
{{{field|Results during intervention|input type=textarea|mandatory|default=?}}}
'''Results after intervention:''' {{#info: ''Results after intervention'' means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.
If a categorization in ''Results during vs. after intervention'' is not possible (e.g. survival data), the results are summarized under ''Results after intervention'' under the headline "Overall".|note}}
{{{field|Results after intervention|input type=textarea|mandatory|default=?}}}
{{{field|Results after intervention|input type=textarea|mandatory|default=?}}}
==Risk of Bias Assessment: Cochrane RoB tool 2.0==
==Risk of Bias Assessment: Cochrane RoB tool 2.0==
{| class="formtable"
{| class="formtable"
! Bias arising from the randomization process
! Bias arising from the randomization process
| {{{field|Bias arising from the randomization process|input type=radiobutton|mandatory|default=?|values=?,low risk,some concerns,high risk}}}
| {{{field|Bias arising from the randomization process|input type=radiobutton|mandatory|default=?|values=?,low risk,some concerns,high risk,NA}}}
|-
|-
! Bias due to deviation from intended intervention (assignment to intervention)  
! Bias due to deviation from intended intervention (assignment to intervention)  
Line 196: Line 200:
|-
|-
! Bias due to missing outcome data
! Bias due to missing outcome data
| {{{field|Bias due to missing outcome data|input type=radiobutton|mandatory|default=?|values=?,low risk,some concerns,high risk}}}
| {{{field|Bias due to missing outcome data|input type=radiobutton|mandatory|default=?|values=?,low risk,some concerns,high risk, NA}}}
|-
|-
! Bias in measurement of the outcome
! Bias in measurement of the outcome
| {{{field|Bias in measurement of the outcome|input type=radiobutton|mandatory|default=?|values=?,low risk,some concerns,high risk}}}
| {{{field|Bias in measurement of the outcome|input type=radiobutton|mandatory|default=?|values=?,low risk,some concerns,high risk, NA}}}
|-
|-
! Bias in selection of the reported result
! Bias in selection of the reported result
| {{{field|Bias in selection of the reported result|input type=radiobutton|mandatory|default=?|values=?,low risk,some concerns,high risk}}}
| {{{field|Bias in selection of the reported result|input type=radiobutton|mandatory|default=?|values=?,low risk,some concerns,high risk,NA}}}
|-
|-
! Other sources of bias
! Other sources of bias
Line 208: Line 212:
|-
|-
! Overall RoB judgment
! Overall RoB judgment
| {{{field|Overall RoB judgment|input type=radiobutton|mandatory|default=?|values=?,low risk,some concerns,high risk}}}
| {{{field|Overall RoB judgment|input type=radiobutton|mandatory|default=?|values=?,low risk,some concerns,high risk,NA}}}
|}
|}


'''Order number:''' {{{field|Order number|input type=text|mandatory|default=1}}}
'''Order number:''' {{{field|Order number|input type=text|mandatory|default=1}}}
'''Outcome topic:''' {{{field|Outcome topic|input type=tokens|mandatory|delimiter=,|values=Aloe vera,Boswellia serrata,Cannabinoids,Carnitine,Curcumin,Electroacupuncture,Enzymes (bromelain papain),Folic acid,Ginger,Ginkgo,Green tea (EGCG),Guarana,Low-carbohydrate or ketogenic diet,Lycopene,Reflexology,Resveratrol,Selenium,Vitamin A (beta-carotene),Vitamin B1,Vitamin B12,Vitamin B6,Vitamin C,Vitamin D,Vitamin E,Zeolites,Zinc,NI,?}}}
{{{end template}}}
{{{end template}}}
{{{for template|Outcome Overview}}}
{{{for template|Outcome Overview}}}
Line 238: Line 244:
| {{{field|power analysis performed|input type=radiobutton|mandatory|default=?}}}
| {{{field|power analysis performed|input type=radiobutton|mandatory|default=?}}}
|-
|-
! Sample size corresponds to power analysis
! style="text-indent:3em;" | - Sample size corresponds to power analysis
| {{{field|Sample size corresponds to power analysis|input type=radiobutton|mandatory|default=?}}}
| {{{field|Sample size corresponds to power analysis|input type=radiobutton|mandatory|default=?}}}
|-
|-
! Reasons for insufficient sample size based on power analysis
! style="text-indent:3em;" | - Reasons for insufficient sample size based on power analysis
| {{{field|Reasons given for samples being too small according to power analysis|input type=textarea|mandatory|default=?}}}
| {{{field|Reasons given for samples being too small according to power analysis|input type=textarea|mandatory|default=?}}}
|-
|-
Line 255: Line 261:
| {{{field|Other explanations for an effect besides the investigated intervention|input type=radiobutton|mandatory|default=?}}}
| {{{field|Other explanations for an effect besides the investigated intervention|input type=radiobutton|mandatory|default=?}}}
|-
|-
! Possibility of attention effects {{#info: e.g. due to lack of a placebo arm|note}}
! style="text-indent:3em;" | - Possibility of attention effects {{#info: e.g. due to lack of a placebo arm|note}}
| {{{field|Possibility of attention effects|input type=textarea|mandatory|default=?}}}
| {{{field|Possibility of attention effects|input type=textarea|mandatory|default=?}}}
|-
|-
! Possibility of placebo effects
! style="text-indent:3em;" | - Possibility of placebo effects
| {{{field|Possibility of placebo effects|input type=textarea|mandatory|default=?}}}
| {{{field|Possibility of placebo effects|input type=textarea|mandatory|default=?}}}
|-
|-
! Other reasons
! style="text-indent:3em;" | - Other reasons
| {{{field|Other reasons|input type=textarea|mandatory|default=?}}}
| {{{field|Other reasons|input type=textarea|mandatory|default=?}}}
|}
|}
Line 274: Line 280:
! Measurement of compliance
! Measurement of compliance
| {{{field|Measurement of compliance|input type=radiobutton|mandatory|default=?}}}
| {{{field|Measurement of compliance|input type=radiobutton|mandatory|default=?}}}
|-
! Blinding reliable
| {{{field|Blinding reliable|input type=radiobutton|mandatory|default=?}}}
|-
! Check whether blinding (of participants) was successful
| {{{field|Check whether blinding was successful|input type=radiobutton|mandatory|default=?}}}
|-
|-
! Consistent reporting in numbers (figures, flowchart, abstract, results)
! Consistent reporting in numbers (figures, flowchart, abstract, results)
Line 290: Line 290:
| {{{field|Cross-over|input type=radiobutton|mandatory|default=?}}}
| {{{field|Cross-over|input type=radiobutton|mandatory|default=?}}}
|-
|-
! Sufficient washout period
! style="text-indent:3em;" | - Sufficient washout period
| {{{field|sufficient washout period|input type=radiobutton|mandatory|default=?}}}
| {{{field|sufficient washout period|input type=radiobutton|mandatory|default=?}}}
|-
|-
! Tested for carry-over effects
! style="text-indent:3em;" | - Tested for carry-over effects
| {{{field|Tested for carry-over effects|input type=radiobutton|mandatory|default=?}}}
| {{{field|Tested for carry-over effects|input type=radiobutton|mandatory|default=?}}}
|-
|-
! Tested for sequence effects
! style="text-indent:3em;" | - Tested for sequence effects
| {{{field|Were sequence effects tested|input type=radiobutton|mandatory|default=?}}}
| {{{field|Were sequence effects tested|input type=radiobutton|mandatory|default=?}}}
|}
|}

Latest revision as of 09:17, 3 December 2024

This is the "RCT Study" form. To create a page with this form, enter the page name below; if a page with that name already exists, you will be sent to a form to edit that page.


Retrieved from "https://camih.med.uni-jena.de/camih/index.php?title=Form:RCT_Study&oldid=7512"